Sonelokimab 120 mg or less showed significant clinical benefit over placebo in patients with plaque psoriasis
1. At 12 weeks, the proportion of patients with an IGA score of 0 or 1 was significantly greater in ...
Tag: chronic plaque psoriasis
Bimekizumab shows better efficacy in treating severe plaque psoriasis than ustekinumab
1. Bimekizumab showed higher efficacy in the treatment of severe plaque psoriasis than ustekinumab with patients showing greater proportion of ...
Bimekizumab is tolerable and efficacious for patients with moderate to severe plaque psoriasis
1. 91% of patients receiving bimekizumab 320 mg every 4 weeks achieved ≥ 90% improvement from baseline in the Psoriasis ...
#VisualAbstract: Roflumilast for chronic plaque psoriasis associated with clearer skin
1. A significantly greater percentage of both roflumilast groups had clear or nearly clear skin compared to the control group ...
Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)
In this randomized controlled trial, 605 patients with moderate-to-severe chronic plaque psoriasis were assigned to receive 150 mg risankizumab subcutaneously ...